



















































































































































































































































































































































Biochemical	results	 	 	 	 	 	
	 Sodium	(mmol/L)	 89	 136.12	 4.28	 126	-	145	 133	-	146	
	 Urea	(mmol/L)	 90	 7.26	 4.36	 1.3	–	33.8	 2.5	-	7.8	
	 Creatinine	(μmol/L)	 90	 79.26	 30.33	 23	-	183	 50	-	130	
	 eGFR	(mL/min/1.73m2)	 90	 72.1	 18.77	 24	-	90	 0-90	







	 	 	 	
	 Adjusted	calcium	(mmol/L)	 89	 2.32	 0.24	 1.65	–	3.5	 2.20	-2.60	
	 Serum	albumin	(g/L)	 90	 32.07	 6.08	 3	-	47	 35	-	50	
	 Serum	osmolarity	(mmol/kg)	 61	 286.36	 10.03	 260	-	311	 275	-	295	
	 Urine	osmolarity	(mmol/kg)	 22	 511.77	 202.83	 174	-	951	 250	-	750	
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Bioelectrical	impedance	 	 	 	 	 	
	 R/H	(Ohm/m)	 90	 341.58	 82.22	 	 	
	 Xc/H	(Ohm/m)	 90	 27.68	 9.49	 	 	
	 PA	(degrees)	 90	 4.71	 1.33	 	 	
	 H2/R	(m2/Ohm)	 90	 51.58	 15.41	 	 	
Morita	Dehydration	Score	 	 	 	 	 	
	 <2	(%)	 38	
(42.2)	
	 	 	 	
	 ≥2	(%)	 52	
(57.8)	
	 	 	 	
Burge-4	score	(mm)	 	 	 	 	 	
	 Total	score	(mm)	 90	 222.07	 95.40	 0	-	400	 	
	 Thirst	(mm)	 90	 56.11	 29.49	 0	-	100	 	
	 Dry	mouth	(mm)	 90	 60.01	 30.64	 0	-	100	 	
	 Unpleasant	taste	(mm)	 90	 42.34	 34.11	 0	-	100	 	
	 Fatigue	(mm)	 90	 63.60	 30.09	 0	-	100	 	















































































Hydration	status	 Male	 Female	 Total	(%)	
Normal	 18	 25	 43	(47.8)	
‘Less	hydrated’	 7	 3	 10	(11.1)	
‘More	hydrated’	 17	 20	 37	(41.1)	





	 ‘Less	hydrated’	(n=10)	 	 ‘Not	less	hydrated’	(n=80)	 	 	
Variable	 Mean	 SD	 	 Mean	 SD	 T	test	 p	
Burge-4	score	(mm)	 257.60	 91.76	 	 217.63	 95.47	 1.25	 0.21	
	 Thirst	 72.70	 22.97	 	 54.04	 29.67	 1.92	 0.06	
	 Dry	mouth	 70.60	 25.80	 	 58.69	 31.07	 1.16	 0.25	
	 Unpleasant	taste	 52.20	 37.51	 	 41.11	 33.71	 0.97	 0.34	
	 Fatigue	 62.10	 23.73	 	 63.79	 30.92	 -0.17	 0.87	
Ur:Cr	ratio	(mmol/mmol)	 137.15	 101.33	 	 91.62	 42.20	 1.41	 0.19	
Na	(mmol/L)	(n=89)	 134.10	 4.77	 	 136.38	 4.17	 -1.60	 0.11	
eGFR	(mL/min/1.73m2)	 71.00	 24.68	 	 72.24	 18.09	 -0.20	 0.85	
AdjCa	(mmol/L)	(n=61)	 2.26	 0.13	 	 2.32	 0.25	 -0.81	 0.42	
Serum	osmalilty	(mosm/kg)	 281.75	 18.46	 	 286.68	 9.38	 -0.95	 0.35	
Albumin	(g/L)	 29.70	 3.95	 	 32.36	 6.25	 -1.31	 0.19	
Urine	osmolality	(mosm/kg)	(n=61)	 540.50	 177.03	 	 505.39	 212.25	 0.31	 0.76	
H2/R		(m2/Ohm)	 39.57	 9.28	 	 53.08	 15.40	 -2.71	 0.008	
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Mann	U	Whitney	test	variable	 Mean	 Rank	 	 Mean	 Rank	 Z	 P	
ECOG	 52.90	 529.00	 	 44.58	 3566.00	 326	 0.32	
Oral	intake	(mLs)	 31.25	 312.5	 	 47.28	 3782.50	 257.5	 0.04	
Morita	Dehydration	Score	 58.60	 586.00	 	 43.86	 3509.00	 269	 0.08	
	 Mucous		 52.45	 524.50	 	 44.63	 3570.50	 330.5	 0.34	
	 Axilla	dryness	 61.00	 610.00	 	 43.56	 3485.00	 245	 0.02	











































Pre-renal	failure	present?	 	 	 	
No	 100.0		 1.00	(ref)	 	
Yes	 44.0		 2.03	(1.26,	
3.26)	
0.003	
Table	6	shows	the	survival	analysis	data	for	participants	according	to	hydration	status	and	
pre-renal	failure	classifications.	
	
The	H2/R	and	the	ur:cr	ratio	remained	significant	predictors	of	survival	following	statistical	
adjustment	(cox	regression)	for	age,	sex,	baseline	ECOG	performance	status	and	cancer	type	
(Table	7).	Cancer	type	also	significantly	influenced	survival	p=0.02.	The	hazard	ratio	for	
death	according	to	the	H2/R	was	0.98	[95%CI=	0.96,	1.00]	(p=	0.04);	this	means	each	unit	
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m2/Ohm	increase	of	the	H2/R	was	associated	with	reduced	probability	of	death	by	a	factor	
of	1.02	(i.e.	1/hazard	ratio).	The	hazard	ratio	for	death	according	to	the	ur:cr	ratio	was	1.01	
[95%CI=	1.00,	1.02],	p=0.001;	this	means	that	each	unit	increase	(mmol:mmol)	of	the	ur:cr	
ratio	was	associated	with	an	increased	probability	of	death	by	a	factor	of	0.99.	
	
Table	7.	Multivariate	cox	regression	analysis	for	death	according	to	age,	performance	
status,	cancer	type,	the	ur:cr	and	the	H2/R	
Variable	 Hazard	Ratio	(95%	CI)	 p	
Age	(years)	 0.99	(0.97,	1.02)	 0.52	
Female	 0.84	(0.47,	1.51)	 0.56	
ECOG	1	 	 0.06	
ECOG	(2	vs.	1)	 1.69	(0.72,	3.96)	 0.23	
ECOG	(3	vs.	1)	 2.82	(1.22,	6.54)	 0.02	
ECOG	(4	vs.	1)	 3.07	(1.17,	8.07)	 0.02	
Cancer	type	(GI)	 	 0.02	
Cancer	type	(Gyne	vs.	GI)	 0.40	(0.13,	1.24)	 0.11	
Cancer	type	(Lung	vs.	GI)	 1.35	(0.67,	2.75)	 0.41	
Cancer	type	(Misc	vs.	GI)	 0.41	(0.20,	0.83)	 0.01	
Cancer	type	(GU	vs	GI)	 0.42	(0.18,	1.00)	 0.05	
Ur:Cr	(mmol/mmol)	 1.01	(1.00,	1.02)	 0.001	
H2/R		(m2/Ohm)	 0.98	(0.96,	1.00)	 0.04	
Table	7	shows	the	cox	regression	analysis	for	death	(hazard	ratio)	according	to	age,	
performance	status	(ECOG),	cancer	type,	the	ur:cr	and	H2/R.	Abbreviations:	GI	=	
gastrointestinal;	Gyne	=	gynecological;	Misc	=	miscellaneous;	GU	=	genitourinary.	
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Fig	5.	Kaplan-Meier	graph	showing	survival	time	in	days	according	to	the	‘less	hydrated’	
classification	(χ2=4.08,	P=0.04)	
	
Tick	marks	indicate	censoring	of	data.		
Fig	6.	Kaplan-Meier	graph	showing	survival	time	in	days	according	to	the	presence	or	
absence	of	pre-renal	failure	(χ2=8.99,	P=0.003)	
	
Tick	marks	indicate	censoring	of	data.		
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Discussion	
Main	findings	and	new	knowledge	
This	is	the	first	study	to	use	BIVA	to	evaluate	hydration	and	its	relationship	with	symptoms	
and	survival	in	advanced	cancer	patients.	The	findings	demonstrate	that	hydration	(as	
measured	by	H2/R	and	BIVA)	in	advanced	cancer	was	significantly	associated	with	physical	
signs	(mucous	membrane	moisture,	axilla	dryness,	sunken	eyes,	oedema),	symptoms	(dry	
mouth,	thirst,	unpleasant	taste,	fatigue)	and	oral	fluid	intake.	Survival	was	statistically	
significantly	shorter	in	‘less-hydrated’	individuals	and	those	with	pre-renal	failure.		
Comparison	with	previous	work	
Our	data	demonstrates	that	the	Morita	Dehydration	Score	was	associated	with	hydration	
status,	which	supports	previous	work	using	this	tool	to	assess	physical	signs	of	
hydration.[32]	In	this	study,	women	had	a	lower	H2/R	compared	to	men,	which	suggests	
comparatively	lower	hydration	volume.	This	finding	is	consistent	with	previous	work[6,	51]	
and	human	physiology,[6,	51,	58,	59]	as	women	normally	have	more	body	fat	than	men	and	
therefore	comparatively	have	less	body	water	in	proportion	to	their	weight.[58,	59]	
Oedematous	participants	had	higher	H2/R	compared	to	non-oedematous	participants,	which	
suggests	they	had	an	increased	hydration	volume.	Although	these	findings	are	consistent	
with	the	literature	it	is	not	possible	to	determine	intracellular	or	extracellular	volumes	
without	the	use	of	regression	equations;	however,	these	equations	have	methodological	
limitations	in	advanced	cancer.[24,	25,	60-62]	
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Our	study	demonstrates	how	higher	Burge-4	scores	were	associated	with	lower	H2/R	(which	
suggests	comparatively	lower	TBW	volume).	Consequently,	our	data	supports	previous	work	
concerning	the	assessment	of	dehydration	symptoms	in	advanced	cancer[36,	40]	and	non-
cancer	populations.[63-67]	Our	analysis	demonstrates	that	lower	oral	fluid	intake	was	
associated	with	‘less	hydrated’	patients.	However,	we	are	unable	to	determine	whether	this	
reduction	in	oral	intake	contributed	to	the	participant’s	hydration	volume,	or	if	it	was	the	
result	of	their	clinical	condition.		
Previous	estimates	of	cancer	dehydration	prevalence	are	generally	based	on	biochemical	
criteria	with	the	prevalence	reported	to	be	60-75%.[68,	69]	In	this	study,	only	11.1%	of	
participants	were	‘less-hydrated’	and	41.1%	were	‘more	hydrated’.	Comparatively,	the	
prevalence	of	pre-renal	failure	in	this	study	was	41.1%,	which	is	consistent	with	previous	
work.[54]	Our	findings	demonstrated	that	(in	this	sample)	individuals	were	more	likely	to	be	
‘more	hydrated’	as	opposed	to	‘less	hydrated’.	This	may	suggest	that	biochemical	
definitions	of	dehydration	lack	sensitivity	in	people	with	advanced	cancer.	Furthermore,	the	
regression	analysis	did	not	detect	a	statistically	significant	association	between	the	ur:cr	
ratio	and	the	H2/R	variables	(Table	3).	This	data	supports	previous	work	that	demonstrates	
how	biochemical	measures	poorly	correlate	with	symptoms	(dry	mouth,	thirst,	fatigue	and	
unpleasant	taste)	in	advanced	cancer.[2,	3,	33,	53,	69,	70]	This	provides	evidence	that	
biochemical	measures	lack	sensitivity	to	predict	hydration-related	symptoms	in	advanced	
cancer.		
Survival	
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Our	data	demonstrates	that	pre-renal	failure	was	associated	with	shorter	survival	in	patients	
with	advanced	cancer,	which	is	consistent	with	previous	research.[71]	Similarly,	the	
Prognosis	in	Palliative	care	Study	(PiPS)	reported	how	an	elevated	urea	measurement	was	a	
predictor	of	shorter	survival	in	patients	with	advanced	cancer.[72]	We	are	unable	to	
determine	the	exact	reason	for	the	association	of	shorter	survival	with	lower	H2/R	and	BIVA	
hydration	status.	However,	it	is	possible	that	‘less	hydrated’	individuals	were	more	likely	to	
have	a	clinical	picture	that	was	associated	with	shorter	survival	(e.g.	cachexia).		
Limitations	
This	study	describes	a	small,	predominantly	Caucasian,	specialist	palliative	care	population	
in	the	last	two	months	of	life.	Only	ten	participants	were	‘less	hydrated’,	which	meant	that	
the	two-group	analysis	was	statistically	limited.	Consequently,	the	ability	to	extrapolate	the	
results	of	this	analysis	to	other	population	groups	is	limited.	This	study	was	observational	
and	therefore	is	unable	to	determine	causation	of	the	studied	variables.	This	analysis	
involved	many	different	cancers	at	various	stages	of	illness.	Survival	was	significantly	
influenced	by	cancer	type,	meaning	some	participants	experienced	shorter	survival	on	
account	of	their	diagnosis.	Consequently,	the	exact	influence	of	hydration	on	survival	is	
difficult	to	determine.	Furthermore,	it	is	possible	that	pre-existing	differences	(related	to	
the	different	cancers)	may	have	caused	variation	in	the	body	composition	of	participants.	
Although	the	H2/R	is	the	single	best	predictor	of	TBW	we	are	unable	estimate	fluid	volume	
without	the	use	of	regression	equations	(which	improve	the	accuracy	of	TBW	measurement	
but	are	methodologically	limited	in	cancer).	Additionally,	the	BIVA	method	is	unable	to	
distinguish	between	fluid	compartments	or	define	intracellular	and	extracellular	fluid	
volumes,	which	limits	our	ability	to	study	these	differences	in	greater	detail.		
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What	is	the	significance	of	the	findings	of	this	analysis?		
This	analysis	provides	evidence	that	hydration	status	is	related	to	physical	signs	(mucous	
membrane	moisture,	axilla	dryness,	sunken	eyes,	oedema),	symptoms	(dry	mouth,	thirst,	
unpleasant	taste,	fatigue),	oral	fluid	intake	and	survival	in	an	advanced	cancer	population.	
These	variables	can	potentially	be	used	to	develop	criteria	for	the	assessment	of	hydration	
status,	for	the	purposes	of	research	and	clinical	practice.	Our	data	reports	no	statistically	
significant	association	between	biochemical	measures	and	hydration	status.	Furthermore,	
we	report	that	(in	this	sample)	a	greater	number	of	participants	were	‘more-hydrated’	
compared	to	those	‘less-hydrated’.	Consequently,	we	recommend	that	healthcare	
professionals	should	carefully	assess	hydration	status	in	their	patients;	it	may	be	possible	for	
individuals	to	be	at	risk	of	fluid	overload	even	though	the	biochemical	results	indicate	pre-
renal	failure.	However,	we	are	unable	to	provide	recommendations	for	the	use	(or	non	use)	
of	CAH	as	this	was	beyond	the	scope	of	this	research	study.		
Future	opportunities	and	research	possibilities		
Future	studies	can	build	on	this	work	and	use	BIVA	to	study	hydration	status	according	to	
specific	cancers,	stratified	by	performance	status,	stage	of	illness,	ethnicity	and	gender.	The	
non-invasive	properties	of	BIVA	provide	the	potential	to	conduct	longitudinal	assessments	
to	study	hydration	and	symptoms	over	time	[28]	(e.g.	the	dying	phase),	in	order	to	
determine	the	clinical	utility	of	CAH.	Further	studies	can	examine	the	potential	use	of	
bioimpedance	for	prognostication.		
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Conclusions		
In	advanced	cancer,	hydration	status	(classified	by	BIA/BIVA)	relates	to	clinically	measurable	
signs	and	symptoms.	Hydration	status	and	pre-renal	failure	were	independent	predictors	of	
survival.	Further	studies	can	establish	the	utility	of	BIVA	as	a	standardised	hydration	
assessment	tool	and	explore	its	potential	research	application,	in	order	to	inform	the	clinical	
management	of	fluid	balance	in	patients	with	advanced	cancer.	
List	of	abbreviations	used		
BIA	=	bioelectrical	impedance	analysis;	BIVA	=	bioelectrical	impedance	vector	analysis;	CAH	
=	clinical	assisted	hydration;	ECOG	=	Eastern	Cooperative	Oncology	Group	performance	
status;	H	=	height;	M	=	mean;	R	=	resistance;	RXc	resistance	reactance;	SNRI	=	Serotonin	and	
norepinephrine	reuptake	inhibitors;	SSRI	=	Selective	serotonin	re-uptake	inhibitors;	Xc	=	
reactance;	TBW	=	total	body	water.	
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